Good MorningEquities shrugged off another hot month of inflation data last week in favor of earnings. The S&P 500 moved up to set a new all-time high on Friday, the question now is whether or not the index can keep it. Along with inflation, the Delta covid variant has emerged as a real threat to the market and could have a serious impact on the second half of the year. Estimates for earnings continue to rise but the pace has slowed over the past week as a rising number of companies warn the market about the second-half outlook.
This week, the focus will be on the consumer. Not only are we expecting a read on retail sales but earnings reports from a host of major retailers including Home Depot and Walmart are due as well. The big-box retailers are expected to post slight YOY revenue declines in the face of last year's tough comparisons.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Markets | |
Inovio (NYSE: INO) stock is trying to hang on to a small gain after the company reported earnings on August 9. Shares of the biotech company are essentially flat for the year, and yet INO stockholders have been taken on a wild ride for much longer than that. There are a couple of reasons for that.... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Consumer Discretionary | | With the way that the sports betting market continues to grow in the United States, there are going to be plenty of opportunities for companies to establish themselves as leaders in this burgeoning industry in the coming years. Bettors are quickly becoming more accustomed to handling their business ... Read the Full Story |
|
Consumer Discretionary | |
High-Flying Cricut, Inc Returns To Earth
Cricut, Inc (NASDAQ: CRCT) caught our attention earlier this year shortly after its IPO. The company's Q1 earnings report was a blowout and opened our eyes to what we see as the new age for crafting. Cricut, Inc provides a range of Internet-connected craft... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Communication Services | | Shares of Disney (NYSE: DIS) look set to end the week on a high as the street digests their Q3 earnings report which was released after Thursday’s session ended. Both the top line and bottom line numbers comfortably beat analyst expectations, with GAAP EPS 60% higher than the consensus and rev... Read the Full Story |
|
Finance | | It’s a bit surprising that capital markets stocks don’t attract more attention from investors and traders, especially given that these companies offer exchange marketplaces where financial securities can be bought and sold. Along with providing a way for traders to buy and sell things li... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Finance | | Brookfield Asset Management (NYSE: BAM) rallied to a new high Wednesday before retreating in Thursday’s session following the company’s second-quarter earnings report.
The stock closed at $56.55 Thursday, down $0.83, or 1.45%. It skidded 4.22% in the first hour of trade, before rallyi... Read the Full Story |
|
Technology | | Digital engagement company Bridgeline Digital (NASDAQ: BLIN) experienced a flood of buying followed by a cascade of selling as a meme stock momentum mover. The Company normally trades under 100,000 shares a day when it was trading in the $2s but experienced a powerful surge in both volume and price ... Read the Full Story |
|
Markets | |
What happens when your employer doesn't offer you a 401(k)? You lose out on money, naturally. Intuitively, you know that. But have you ever stopped to calculate just how much you're losing out on if you don't have an employer plan?
Employer-sponsored 401(k) plans have turned into one of the most ... Read the Full Story |
|
Communication Services | |
Shares of The Trade Desk (NASDAQ: TTD) have been on a roller coaster after a stellar earnings report. However, TTD stock continues to establish higher levels of support. And the stock is within range of its 52-week high set at the end of December.
If analyst sentiment is any indication, that sh... Read the Full Story |
|
Markets | | Electrical wiring manufacturer Emcore Wire Corporation (NASDAQ: WIRE) stock surged on its absolute blowout Q2 2021 earnings causing shares to violently reverse the downtrend and surge back up to all-time highs. The massive earnings blowout was largely due to rise in copper prices in addition to the ... Read the Full Story |
|
The Early Bird Stock Of The Day Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. | | View Today's Stock Pick |
|
